Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
This article was originally published in The Pink Sheet Daily
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.
You may also be interested in...
FDA objects to image and headline on Actavis webpage suggesting benign prostatic hyperplasia treatment improves sleep quality and work productivity; company has revised the site.